Cargando…

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer

BACKGROUND: Topotecan is the standard second line agent used in relapsed small cell lung cancer (SCLC). However, the erratic availability and the cost of the drug has been a prohibitive factor for its use in second-line setting in India. Paclitaxel has shown antitumor activity in heavily pretreated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noronha, Vanita, Sahu, Arvind, Patil, Vijay M., Joshi, Amit, Ramaswamy, Anant, Chandrasekharan, Arun, Kadam, Nandkumar, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	METRONOMIC THERAPY IN LUNG CANCER: Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873701/ https://www.ncbi.nlm.nih.gov/pubmed/27275452 http://dx.doi.org/10.4103/2278-330X.181643

Ejemplares similares

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
por: Pandey, Avinash, et al.
Publicado: (2016)

Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India
por: Pandey, Avinash, et al.
Publicado: (2016)

Metronomic therapy with oral 6-mercaptopurine in elderly acute myeloid leukemia: A prospective pilot study
por: Kapoor, Akhil, et al.
Publicado: (2016)

An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients
por: Patil, Vijay M., et al.
Publicado: (2016)

Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal
por: Noronha, Vanita, et al.
Publicado: (2015)

Palliative chemotherapy in carcinoma nasopharynx
por: Patil, Vijay M., et al.
Publicado: (2019)

Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
por: Patil, Vijay, et al.
Publicado: (2018)

Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers
por: Patil, Vijay M., et al.
Publicado: (2015)

Long term outcomes of phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early failure oral cancer
por: Babanrao Dhumal, Sachin, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC)
por: Kashyap1, Lakhan, et al.
Publicado: (2021)

Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach
por: Patil, Vijay, et al.
Publicado: (2018)

Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center
por: Ramaswamy, Anant, et al.
Publicado: (2017)

Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy
por: Dhumal, Sachin Babanrao, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
por: Noronha, Vanita, et al.
Publicado: (2012)

Metronomic adjuvant chemotherapy evaluation in locally advanced head and neck cancers post radical chemoradiation – a randomised trial
por: Patil, Vijay, et al.
Publicado: (2023)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
por: Patil, Vijay, et al.
Publicado: (2021)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

Aggressive Surgery in Palliative Setting of Lung Cancer: Is it Helpful?
por: Byregowda, Suman, et al.
Publicado: (2016)

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
por: Patil, Vijay M., et al.
Publicado: (2016)

Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis
por: Agarwala, Vivek, et al.
Publicado: (2018)

Crizotinib: A comprehensive review
por: Sahu, Arvind, et al.
Publicado: (2013)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment
por: Kumar, D. Santhosh, et al.
Publicado: (2014)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Resistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab
por: Pandey, Avinash, et al.
Publicado: (2013)

Lung cancer in the Indian subcontinent
por: Noronha, Vanita, et al.
Publicado: (2016)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
por: Butle, Ashwin, et al.
Publicado: (2021)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_090ga7kgrbdu1hrrii2d5chna0